Key Takeaways MEDX touched a new 52-week high, rising 49.9% from its $23.46 low.The ETF targets patented first-line pharma and biologics, charging 85 bps in fees.A 28.43 weighted alpha signals potential for further near-term gains.For investors seeking momentum, the Horizon Kinetics Medical ETF (MEDX) is probably on the radar now. The fund just hit a 52-week high and is up 49.9% from its 52-week low price of $23.46 per share.  But are there more gains in store for this ETF? Let’s take a quick look at the fu ...

February 13, 2026 02:50 AM GMT 亚洲经济研究 | Asia Pacific Morgan Stanley Asia Limited Chetan Ahya 亚洲首席经济学家 Chetan.Ahya@morganstanley.com +852 2239-7812 Morgan Stanley Asia (Singapore) Pte. 甘永康 亚洲经济学家 Derrick.Kam@morganstanley.com +65 6834-8272 Morgan Stanley Asia Limited M Idea 观点：市场反馈与我们的共识 和分歧 投资者整体对亚洲持积极看法，但关注点主要集中在科技板 块；而我们认为复苏正在向非科技板块扩散。这意味着，在 相对配置层面，投资者更看好北亚（不含中国）。投资者在 微观层面对中国保持乐观，但同时也认可宏观层面所面临的 挑战。 要点 在本报告中，我们就以下与投资者反复讨论的关键议题，分享我们的看法： This translated report is made available for convenience only and is ba ...

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, will highlight the Company’s Gene Circuit technology platform, pipeline progress and strategic priorities, with an emphasis on opportunities for partnership across i ...

Core Insights - Kraig Biocraft Laboratories (OTCQB: KBLB) is featured on the cover of the March issue of National Geographic, highlighting a significant scientific breakthrough in the production of spider silk, a material known for its exceptional strength and toughness [1][8]. Company Overview - Kraig Biocraft Laboratories is a biotechnology company focused on developing and commercializing spider silk-based fiber technologies, utilizing genetically engineered silkworms to produce high-performance, cost-effective, and scalable spider silk materials for various applications [10]. Scientific Breakthrough - The article titled "Unlocking Nature's Miracle" discusses the global effort to manufacture spider silk, emphasizing the transition of spider silk from a laboratory curiosity to a scalable biomaterial [1][3]. - Spider silk's extraordinary properties are attributed to specialized proteins called spidroins, which form fibers with unmatched tensile strength, elasticity, and toughness [4]. Production Method - The company has developed genetically engineered silkworm strains that can produce recombinant spider silk proteins, leveraging the silkworm's natural spinning system to create a viable production method [5][6]. - This production method is positioned alongside other international efforts, including fermentation-driven systems, providing a comprehensive overview of the advancements in the field [6]. Market Relevance - The March issue of National Geographic serves as a significant resource for readers interested in advanced materials, synthetic biology, and sustainable fibers, marking a growing mainstream interest in the field of recombinant biomaterials [7][8].

分组1 - Travere Therapeutics reported 4Q25 non-GAAP EPS of $0.37, aligning with expectations [1] - Revenue for the quarter was $129.6 million, representing a 73% year-over-year increase, but fell short of consensus by approximately $18 million [1]

WOODBRIDGE, Conn.--(BUSINESS WIRE)--LambdaVision, an innovative biotech company developing a protein-based artificial retina to help patients regain sight lost to retinal degenerative diseases, is advancing its commercialization efforts by pre-booking commercial space in low-Earth orbit (LEO) through partnerships with Starlab Space LLC, a joint venture led by Voyager Technologies. This strategic agreement supports LambdaVision's plan to scale manufacturing of its protein-based artificial retina. ...

SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer, and Felipe Duran, Chief Financial Officer, will participate in fireside chats at the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the Leerink Global Healthcare Conference. Oppenheimer 36th Annual Healthcare Life Sciences ConferencePresentation Date: Thursday, Fe ...

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the TD Cowen 46th Annual Healthcare Conference in Boston, MA, from March 2-4, 2026 and will participate in a fireside chat on March 3, 2026 at 10:30am ET. A live audio webcast of this event will be accessible from the "Events†page of the Investors section of the C ...

Company Performance - Hims & Hers Health, Inc. (HIMS) reported a 4Q25 GAAP earnings per share of $0.08, exceeding expectations by approximately $0.03 [1] - Revenue for the quarter was $617.82 million, which was essentially in line with forecasts [1] Analyst Background - The analyst has a Master's degree in Cell Biology and extensive experience in drug discovery, focusing on biotechnology companies that innovate through unique mechanisms and therapies [1] - The analyst combines scientific expertise with financial analysis to deliver technically sound and investment-driven research [1] Investment Focus - The focus is on evaluating the science behind drug candidates, the competitive landscape, clinical trial design, and potential market opportunities while balancing financial fundamentals [1] - The goal is to provide insights that help investors understand both opportunities and risks in the biotech sector, which can yield significant returns but requires careful scrutiny [1]

Group 1 - Frontier Biotechnologies has entered into a deal with GSK, granting GSK worldwide rights to develop two small interfering RNA therapies targeting kidney diseases [1] - The agreement could be worth up to $1 billion, indicating significant potential for both companies in the biopharmaceutical market [1] - This collaboration highlights the growing interest and investment in RNA-based therapies within the healthcare and pharmaceutical industry [1]